LimmaTech Biologics further develops AbVacc vaccine

21 December 2023 09:19

Zurich CCGreater ZurichSwiss AMCHAM SoCal

Schlieren/Rockville - LimmaTech Biologics has secured the rights to further develop a vaccine candidate from AbVacc. It is designed to protect against diseases caused by a specific bacterium. The biotech company will also receive an exclusive option to acquire all worldwide rights.

The Schlieren-based biotech company LimmaTech Biologics has signed a license agreement with the US company AbVacc from Rockville, Maryland, according to a statement. As part of this agreement, it will further develop AbVacc's vaccine candidate LBT-SA7, which is designed to protect against diseases caused by the bacterium Staphylococcus aureus. In addition to skin infections, these include diseases such as pneumonia.

LimmaTech Biologics will initially conduct a Phase I clinical trial in the coming year. The company also has an exclusive option to acquire all worldwide rights to the vaccine if the trial is successful. “S. aureus-related infections remain an urgent global medical priority, for which there is no vaccine currently available,” said Franz-Werner Haas, CEO of LimmaTech Biologics, in the statement. 

LimmaTech Biologics already has experience in the development of vaccines, including candidates related to Staphylococcus aureus. Haas sees the license agreement with AbVacc as a further milestone in the company's strategy to prevent untreatable microbial infections and positively impact the rise in antimicrobial resistance.

LimmaTech Biologics is based in Schlieren in the canton of Zurich and is a member of the Bio-Technopark Schlieren-Zurich. ce/ssp

Swiss Pavilion Digital

Previous newsletters